Literature DB >> 27847965

Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases.

Jingping Hu1,2, Mao Ye3, Zhiguang Zhou4,5.   

Abstract

Diabetes mellitus is one of the most common chronic diseases that threatens human health in worldwide populations. Despite enormous efforts invested in the study of diabetes mellitus, the development of precise diagnoses and treatments for this disease remains difficult due to the limitations of current techniques. Therefore, new methods are currently being developed. Aptamers are oligonucleotides that bind to specific target molecules and have been widely applied as diagnostic and therapeutic tools. In recent years, aptamers have been utilized in the study of diabetes mellitus and metabolic diseases. In this review, we highlight recent developments and new perspectives on aptamers in the field of diabetes mellitus and other metabolic diseases. Aptamers could potentially provide the means for efficient diagnoses and therapies against diabetes mellitus.

Entities:  

Keywords:  Aptamers; Diabetes mellitus; Oligonucleotides

Mesh：

Substances：

Year:  2016        PMID： 27847965     DOI： 10.1007/s00109-016-1485-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


  94 in total

1.  Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer.

Authors:  J Colin Cox; Andrew Hayhurst; Jay Hesselberth; Travis S Bayer; George Georgiou; Andrew D Ellington
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

2.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

3.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

Authors:  P Shah; A Vella; A Basu; R Basu; W F Schwenk; R A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

4.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 5.  Mechanisms of diabetic complications.

Authors:  Josephine M Forbes; Mark E Cooper
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

6.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.

Authors:  Timothy E Graham; Qin Yang; Matthias Blüher; Ann Hammarstedt; Theodore P Ciaraldi; Robert R Henry; Christopher J Wason; Andreas Oberbach; Per-Anders Jansson; Ulf Smith; Barbara B Kahn
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

7.  Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance.

Authors:  Markus Hafner; Anton Schmitz; Imke Grüne; Seergazhi G Srivatsan; Bianca Paul; Waldemar Kolanus; Thomas Quast; Elisabeth Kremmer; Inga Bauer; Michael Famulok
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

Review 8.  Current progress of aptamer-based molecular imaging.

Authors:  Andrew Z Wang; Omid C Farokhzad
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

Review 9.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

Review 10.  Insulin as a physiological modulator of glucagon secretion.

Authors:  Pritpal Bansal; Qinghua Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-22       Impact factor: 4.310
View more
  6 in total

Review 1.  Recent Microdevice-Based Aptamer Sensors.

Authors:  Donny Nugraha Mazaafrianto; Masatoshi Maeki; Akihiko Ishida; Hirofumi Tani; Manabu Tokeshi
Journal:  Micromachines (Basel)       Date:  2018-04-25       Impact factor: 2.891

2.  Ergosterol Ameliorates Diabetic Nephropathy by Attenuating Mesangial Cell Proliferation and Extracellular Matrix Deposition via the TGF-β1/Smad2 Signaling Pathway.

Authors:  Zhonghua Dong; Yueyue Sun; Guangwei Wei; Siying Li; Zhongxi Zhao
Journal:  Nutrients       Date:  2019-02-25       Impact factor: 5.717

3.  A survey on glycemic control rate of type 2 diabetes mellitus with different therapies and patients' satisfaction in China.

Authors:  Qiaoliang Dong; Jin Huang; Shunying Liu; Lingfeng Yang; Juan Li; Bei Li; Xue Zhao; Zaizhao Li; Liaofang Wu
Journal:  Patient Prefer Adherence       Date:  2019-07-31       Impact factor: 2.711

4.  Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice.

Authors:  Binghua Xue; Xiuxiao Xiao; Tingting Yu; Xinhua Xiao; Jing Xie; Qiuhe Ji; Li Wang; Tao Na; Shufang Meng; Lingjia Qian; Haifeng Duan
Journal:  Stem Cell Res Ther       Date:  2021-02-15       Impact factor: 6.832

5.  miR-136 improves renal fibrosis in diabetic rats by targeting down-regulation of tyrosine kinase SYK and inhibition of TGF-β1/Smad3 signaling pathway.

Authors:  Lei Liu; Xinlu Pang; Wenjun Shang; Guiwen Feng; Zhigang Wang; Junxiang Wang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

6.  Diosgenin reduces phosphodiesterase 3B (PDE3B) through AMP-activated protein kinase/ mechanistic target of rapamycin (AMPK/mTOR) signaling pathway to ameliorate streptozotocin-induced pancreatic β-cell apoptosis and dysfunction.

Authors:  Lijie Ma; Chengfei Zhang; Lili Wu; Lingling Qin; Tonghua Liu
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.